Articles tagged with Glaucoma
Researchers found that glaucoma patients have higher intraocular pressure when lying down compared to sitting. The study measured the pressure of 148 untreated glaucoma patients over 24 hours, revealing a significant difference in peak pressures between daytime and nighttime measurements.
A study published in Archives of Ophthalmology found that patients with end-stage glaucoma consume approximately $2,511 per year in healthcare resources, compared to $623 for those with early-stage disease. Effective treatments at earlier stages can slow or halt disease progression, saving both patients and society from greater economi...
The study found that direct ophthalmology-related resource use increased with disease severity, resulting in higher costs. The average direct cost of treatment ranged from $623 to $2,511 per patient per year, with medication costs being the largest proportion of total direct cost.
Researchers developed a risk calculator to assess patient risk levels and recommend treatment options for patients with ocular hypertension. The tool identifies key factors predictive of disease progression, enabling physicians to make informed decisions about treatment.
A recent study by the American Academy of Ophthalmology reveals that many glaucoma patients fail to take their medication properly, with up to half delaying refills or missing doses. This non-adherence can lead to increased hospital admissions and lost productivity, resulting in significant economic costs worldwide.
Researchers found that individuals with high transferrin saturation levels have a 2.24 times greater relative risk of cancer when consuming excessive iron intake, emphasizing the need for dietary restrictions to mitigate this risk. Additionally, a study analyzing over 35,000 participants revealed that family-level influences significan...
Researchers found that high-dose gamma radiation and bone marrow transfer prevented glaucoma in mice by blocking neurodegeneration. The treatment, which is already used for human cancers, may also offer protection against other neurodegenerative diseases like Alzheimer's and Parkinson's.
The January 2005 issue of the American Academy of Ophthalmology's Journal features various studies on glaucoma, including the restoration of retinal ganglion cell function in early glaucoma after intraocular pressure reduction. Other topics include LASIK surgery and its effects on myopia, as well as a study on familial aggregation of h...
Columbia University Irving Medical Center affiliate Harlem Hospital Center will fund aggressive screening program for glaucoma, which disproportionately affects African Americans. The hospital has demonstrated an impressive job in screening the community for this devastating condition.
The American Academy of Ophthalmology published a comprehensive collection of 60 case studies covering diverse ophthalmic topics including sebaceous carcinoma, refractive errors, glaucoma, and more. The studies provide valuable insights into the diagnosis and management of various eye conditions.
Columbia researchers found that patients with thinner or thicker corneas need different IOP adjustments for effective glaucoma treatment. The study's linear correction scale significantly impacted treatment decisions, highlighting the importance of CCT in managing the condition.
The study found that central corneal thickness significantly impacts clinical management decisions for patients with glaucoma. Adjustments in therapy, including eye drops, laser therapy, and surgery, were made based on CCT measurements, affecting approximately 8-10% of patients.
A new approach to assessing glaucoma risk, inspired by the coronary heart disease model, aims to identify individuals at risk and guide treatment decisions. This initiative has the potential to shift the focus from reactive treatment to proactive prevention and earlier intervention for those at risk.
A new portable device called the Newton TM has been developed to detect glaucoma, a leading cause of blindness. The device is more accurate than previous models and can be used in various positions, making it ideal for early detection and treatment.
Researchers successfully delivered a phosphorescent green protein from jellyfish to the eyes of laboratory cats, producing a permanent effect. The study demonstrates a potential gene therapy approach to treat glaucoma, a chronic disease affecting 70 million people worldwide.
This September 2004 issue of Ophthalmology journal features groundbreaking research on predictive factors for glaucomatous visual field progression, primary open-angle glaucoma in Japan, and hypothyroidism's impact on open-angle glaucoma. The studies also explore the mechanism of ocular hypotensive action of bimatoprost and optic nerve...
A significant association has been found between hypothyroidism and an increased risk of developing glaucoma in men. Researchers analyzed data from nearly 6,000 male patients with newly diagnosed glaucoma, revealing that nearly 7% had a prior diagnosis of hypothyroidism compared to 4% of non-glaucoma patients.
Researchers have identified key genes involved in regulating eye pressure, which could lead to new treatments for glaucoma. The study found that two proteins, matrix Gla protein and perlecan, help maintain normal pressure by keeping the trabecular meshwork soft.
The Los Angeles Latino Eye Study investigated the prevalence of open-angle glaucoma and ocular hypertension in Latinos. The study also explored changes in retinal nerve fiber layer thickness after acute primary angle closure. Additionally, researchers examined the impact of cataract on frequency-doubling technology perimetry results.
Researchers at Imperial College London have developed sugar-like molecules that mimic the body's immune defense mechanisms to prevent scarring after glaucoma eye surgery. These new drugs show a dramatic increase in success rates from 30% to 80%, offering hope for patients with this condition.
A study found latanoprost to be safe and well-tolerated in reducing intraocular pressure (IOP) for patients with primary open-angle and exfoliation glaucoma. The researchers also reported a mild incidence of increased iris pigmentation, primarily affecting patients with green-brown or yellow-brown eyes.
A study published in Archives of Ophthalmology found that long-term use of statins and nonstatin cholesterol-lowering medications was associated with a reduced risk of open-angle glaucoma. The study included 667 men with new diagnoses of glaucoma between 1997 and 2001.
African American participants who received pressure-lowering eye drops had a lower risk of developing glaucoma compared to those who didn't receive treatment. Regular eye exams are crucial for determining glaucoma risk, particularly in African Americans over 40.
The study found that daily pressure-lowering eye drops reduced the development of primary open-angle glaucoma in African Americans by almost 50%. This suggests that comprehensive dilated eye examinations should be recommended at least once every two years for African Americans over age 40.
Glaucoma is a group of disorders that progressively damage the optic nerve, affecting 66 million people worldwide. Early detection through comprehensive eye assessments, including optic disc examination, is crucial for limiting vision loss and advancing treatment. Current therapies can limit vision loss if identified in early stages.
The study projects that vision loss from eye diseases will reach 5.5 million Americans by 2020, with age-related macular degeneration, glaucoma, and cataract being the most common causes. Regular comprehensive eye exams are crucial for preventing and/or delaying eye disease in those at higher risk.
A study estimates that 937,000 Americans are blind, with white persons affected by age-related macular degeneration. The prevalence of visual impairment is expected to increase due to aging, with blacks and Hispanics more likely to be affected by cataracts and glaucoma.
This issue of the January 2004 Ophthalmology journal presents a range of studies on LASIK complications, including night vision issues and corneal epithelial adhesion abnormalities. Researchers also explore various eye diseases, such as retinal tears, glaucoma, and macular degeneration.
Researchers found that model mice with pigment dispersion glaucoma had abnormal immune responses in their eyes, which preceded disease onset. The study suggests that loss of immune privilege may trigger the development of glaucoma.
A landmark study conducted by the University of Southern California found that nearly two-thirds of Latino participants with diabetes were not following American Diabetes Association guidelines for vision care, leading to higher rates of diabetic retinopathy, early macular degeneration, and glaucoma among this ethnic group.
Researchers discovered that a gene mutation in mice leads to severe glaucoma by disrupting ocular drainage structures. Administering L-DOPA to pregnant mice with the mutation improved pup outcomes, suggesting potential therapeutic benefits.
Researchers discovered a new gene mutation that affects L-DOPA production, potentially leading to new treatments for glaucoma. The study found that administering L-DOPA prevented severe abnormalities in mice with a genetic defect similar to primary congenital glaucoma.
Researchers have developed a new technology using adaptive optics to improve diagnosis of eye diseases. The technology enables doctors to see individual cells in the retina, allowing for early detection and treatment of conditions such as glaucoma and age-related macular degeneration.
Researchers found that treating people with early-stage glaucoma immediately can delay disease progression and slow vision loss. The study followed 255 patients with early stage glaucoma in at least one eye, finding that treatment led to a slower rate of disease progression.
Nearly a third of surveyed glaucoma patients reported difficulties with taking multiple medications, citing missed dosing and inadequate waiting periods. Physicians advocate for more patient education and convenient treatments to improve compliance and vision outcomes.
A recent study found that eye drops can delay the onset of glaucoma by reducing intraocular pressure by approximately 20%. The Ocular Hypertension Treatment Study (OHTS) followed 1,636 participants with elevated eye pressure and showed a significant reduction in glaucoma development among those who received treatment. This breakthrough...
A survey found that few Americans are aware of ocular hypertension, with only 41% recognizing it as a factor in glaucoma risk. Many individuals over 40 years old are unaware they need routine screening for the condition, despite being at increased risk.
Researchers found that pressure-lowering eye drops reduced the development of primary open-angle glaucoma by more than 50% in high-risk individuals. The study also highlighted personal and ocular risk factors associated with glaucoma development.
A recent study found that pressure-lowering eye drops reduced the development of primary open-angle glaucoma by over 50 percent. The study suggests that treating people with elevated eye pressure may delay or prevent glaucoma, particularly in those at higher risk due to age, ethnicity, or ocular characteristics.
A study found XALACOM to be more effective than Cosopt in reducing intraocular pressure by 1.00 mmHg, with fewer reported eye pain and irritation. XALACOM was also well-tolerated systemically, with no taste disturbances reported.
A total of 825 patients with primary open-angle glaucoma or ocular hypertension showed significant improvements in intraocular pressure after switching to XALATAN. The study found that 83% of patients experienced a reduction in IOP due to inadequate control, and 90% of those who switched due to adverse events maintained IOP control.
A five-year study demonstrated Xalatan's efficacy in managing open-angle glaucoma by reducing intraocular pressure (IOP) sustainably. The treatment was well-tolerated, controlling IOP without surgery in 72% of patients.
A recent study found that glaucoma was the most common cause of blindness among Hispanics, accounting for 0.3% of the population, with open-angle glaucoma being the leading cause. The prevalence of visual impairment increased with age, with cataract and age-related macular degeneration also being significant causes.
A study published in Archives of Ophthalmology found that glaucoma affects approximately 0.5% of people aged 41-49 and up to 12% of those aged 80+, with women being disproportionately affected. The high prevalence among Mexican-Americans may be attributed to barriers such as cost of care and distrust of majority culture.
A study by researchers at Johns Hopkins and two other academic medical centers found that large fluctuations in eye pressure during the day or over consecutive days are associated with greater risk of vision loss. Glaucoma patients who experienced low fluctuations in pressure had a lower risk of further vision loss compared to those wi...
Glaucoma is now understood as a neurodegenerative disease affecting the entire visual system, including brain cells. Researchers found that forty percent of nerve cells in both eye and brain are destroyed by the disease.
Researchers at Washington University School of Medicine have identified a potential new approach to treating glaucoma by inhibiting an enzyme that produces excessive nitric oxide, leading to cell damage. The study found that rats with elevated eye pressure lost less than 10% of their retinal ganglion cells when treated with the inhibitor.
Dr. Satcher addresses the American Chemical Society on building a better community health system, honoring black chemist Percy Julian's discovery of glaucoma treatment. He shares insights on opportunities and challenges for a balanced community health system.
Researchers have discovered a key role for the TIGR protein in non-hereditary forms of glaucoma, which may lead to novel diagnostic tools and treatments. The study found that exposure to steroid drugs or oxidative stress increased TIGR protein production, contributing to elevated intraocular pressure.
A groundbreaking study has identified a gene responsible for primary congenital glaucoma, a condition affecting 1 in 2,000 to 1 in 10,000 births. The discovery holds promise for early diagnosis and treatment, potentially preventing blindness, with the potential to be applied to adult-onset primary open angle glaucoma.
Scientists have discovered a new gene that causes Rieger syndrome, a rare disorder affecting tooth development and leading to glaucoma in 50% of cases. The RGS gene is similar in structure to genes found in fruit flies and mice, suggesting its role in human development.